After holding leadership positions at contract manufacturers Patheon and Thermo Fisher Scientific, working in the food and ...

StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT – Free Report) in a research note issued to investors on Saturday morning. The brokerage issued a hold rating on the stock.

Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

Healthcare proved to be a resilient market for mergers and acquisitions in 2024, despite deal volume declining 9% from 2023. ...

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

2024 was quite a year for significant strategic action among the pharmaceutical giants. Here are five key trends that will ...

The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This Semaglutides market report covers market characteristics, size and growth, segmentation, regional ...

M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next ...

The transaction – first announced in February – would see Novo Nordisk's parent company Novo Holdings buy contract development and manufacturing organisation (CDMO) Catalent outright for $16.5 ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...